196 related articles for article (PubMed ID: 26620594)
1. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
Cosco D; Cilurzo F; Maiuolo J; Federico C; Di Martino MT; Cristiano MC; Tassone P; Fresta M; Paolino D
Sci Rep; 2015 Dec; 5():17579. PubMed ID: 26620594
[TBL] [Abstract][Full Text] [Related]
2. Microscopic and spectroscopic evaluation of novel PLGA-chitosan Nanoplexes as an ocular delivery system.
Jain GK; Pathan SA; Akhter S; Jayabalan N; Talegaonkar S; Khar RK; Ahmad FJ
Colloids Surf B Biointerfaces; 2011 Feb; 82(2):397-403. PubMed ID: 20940097
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes.
Cosco D; Federico C; Maiuolo J; Bulotta S; Molinaro R; Paolino D; Tassone P; Fresta M
Int J Nanomedicine; 2014; 9():2359-72. PubMed ID: 24876772
[TBL] [Abstract][Full Text] [Related]
4. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
5. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells.
Kaban K; Salva E; Akbuga J
Nucleic Acid Ther; 2017 Feb; 27(1):45-55. PubMed ID: 27763825
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
Di Martino MT; Campani V; Misso G; Gallo Cantafio ME; Gullà A; Foresta U; Guzzi PH; Castellano M; Grimaldi A; Gigantino V; Franco R; Lusa S; Cannataro M; Tagliaferri P; De Rosa G; Tassone P; Caraglia M
PLoS One; 2014; 9(2):e90005. PubMed ID: 24587182
[TBL] [Abstract][Full Text] [Related]
8. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer.
Zeng X; Tao W; Mei L; Huang L; Tan C; Feng SS
Biomaterials; 2013 Aug; 34(25):6058-67. PubMed ID: 23694904
[TBL] [Abstract][Full Text] [Related]
9. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
10. N-lauroyl chitosan surface-modified PLGA nanoparticles as carrier for adriamycin to overcome cancer drug resistance.
Li J; Zhou P; Wang Y; Chen H; Zhang C; Li R; Yang X; Wang Y
J Microencapsul; 2014; 31(3):203-10. PubMed ID: 23937210
[TBL] [Abstract][Full Text] [Related]
11. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
13. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
14. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
[TBL] [Abstract][Full Text] [Related]
15. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
16. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating.
Jagani HV; Josyula VR; Palanimuthu VR; Hariharapura RC; Gang SS
Eur J Pharm Sci; 2013 Mar; 48(4-5):611-8. PubMed ID: 23291045
[TBL] [Abstract][Full Text] [Related]
17. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
Simonoska Crcarevska M; Geskovski N; Calis S; Dimchevska S; Kuzmanovska S; Petruševski G; Kajdžanoska M; Ugarkovic S; Goracinova K
Eur J Pharm Sci; 2013 Apr; 49(1):65-80. PubMed ID: 23439240
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
[TBL] [Abstract][Full Text] [Related]
20. PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: new carriers for DNA delivery.
Nie H; Lee LY; Tong H; Wang CH
J Control Release; 2008 Aug; 129(3):207-14. PubMed ID: 18539352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
